Clinic
Texas Health Arlington Memorial Hospital
Texas Health Arlington Memorial Hospital was paid $8.23M by Medicaid between Sep 2018 and Dec 2024, across 124 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoTEXAS HEALTH ARLINGTON MEMORIAL HOSPITAL
ARLINGTON, TX 76012
ARLINGTON, TX 76012
33aNPI1174533343assigned 08/09/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$8.23M
24GClaims204,251
24DCodes billed124
24AFirst – last monthSep 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#54 of 320
Median peer was paid$205K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MINCHER, JEFF controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14 | $25.49 | |
| 2019 | 90 | $582.59 | |
| 2020 | 3,057 | $146K | |
| 2021 | 49,258 | $1.56M | |
| 2022 | 66,713 | $2.41M | |
| 2023 | 62,270 | $2.90M | |
| 2024incomplete | 22,849 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 16,487 | 15,235 | $2.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 21,077 | 19,998 | $1.13M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 11% | 6,035 | 5,792 | $875K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 2,621 | 2,389 | $515K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 5,199 | 1,253 | $384K |
| 71045 | Radiologic examination, chest; single view | 2.5% | 7,235 | 6,698 | $202K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.2% | 10,379 | 9,919 | $178K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 879 | 840 | $164K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 1,996 | 1,661 | $159K |
| 80053 | Comprehensive metabolic panel | 1.9% | 12,368 | 10,974 | $158K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 20,183 | 17,796 | $146K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 1,872 | 1,824 | $144K |
112 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 4,055 | $105K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,233 | $78K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 615 | $60K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,895 | $55K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,067 | $51K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,232 | $50K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 352 | $44K |
| 76801 | <1% | 630 | $44K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 927 | $43K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 970 | $42K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,750 | $41K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,628 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,387 | $36K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 65 | $31K |
| 83880 | <1% | 1,595 | $31K | |
| 87800 | <1% | 821 | $26K | |
| 81001 | <1% | 8,551 | $25K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 457 | $24K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 275 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,319 | $24K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 179 | $23K |
| 84484 | <1% | 3,149 | $22K | |
| CP007 | <1% | 497 | $22K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,702 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 548 | $19K |
| 93976 | <1% | 284 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,406 | $16K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 667 | $16K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 545 | $15K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 943 | $15K |
| 84703 | <1% | 2,425 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,061 | $13K |
| 81025 | <1% | 1,835 | $12K | |
| 84702 | <1% | 1,158 | $12K | |
| 83690 | <1% | 2,842 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 196 | $11K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 764 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,546 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 220 | $9K |
| 93975 | <1% | 43 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 360 | $7K |
| 86780 | <1% | 768 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,395 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 110 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 706 | $5K |
| 86850 | <1% | 350 | $5K | |
| 87634 | <1% | 77 | $5K | |
| 83735 | <1% | 1,221 | $5K | |
| 83605 | <1% | 606 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 856 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 60 | $4K |
| 82947 | <1% | 984 | $4K | |
| 85730 | <1% | 977 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 84 | $3K |
| 97161 | <1% | 57 | $3K | |
| 85610 | <1% | 1,259 | $3K | |
| 87040 | <1% | 435 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 48 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 740 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,926 | $3K |
| 94760 | <1% | 114 | $3K | |
| 86900 | <1% | 1,284 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,148 | $3K |
| 82951 | <1% | 297 | $3K | |
| 86901 | <1% | 1,193 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 38 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 115 | $2K |
| 80076 | <1% | 252 | $2K | |
| 85379 | <1% | 483 | $2K | |
| 84145 | <1% | 59 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 28 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 253 | $1K |
| 86803 | <1% | 166 | $1K | |
| 96376 | <1% | 113 | $1K | |
| 81003 | <1% | 885 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 209 | $1K |
| 85027 | <1% | 264 | $1K | |
| 86762 | <1% | 139 | $1K | |
| 90715 | <1% | 110 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,210 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 55 | $906.51 |
| 87340 | <1% | 125 | $824.65 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,091 | $649.02 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 110 | $636.70 |
| 86787 | <1% | 92 | $621.75 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 144 | $609.07 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 542 | $575.25 |
| 83021 | <1% | 57 | $529.92 | |
| 90686 | <1% | 143 | $482.20 | |
| 73562 | <1% | 12 | $413.05 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14 | $366.16 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 638 | $365.22 |
| 0352U | <1% | 110 | $333.87 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 125 | $308.98 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 325 | $228.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 301 | $202.29 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 71 | $136.28 |
| 80047 | <1% | 17 | $110.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 315 | $102.30 |
| 81511 | <1% | 13 | $94.70 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 109 | $92.95 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 16 | $87.12 |
| 85014 | <1% | 34 | $83.85 | |
| 90656 | <1% | 17 | $70.64 | |
| 86140 | <1% | 15 | $68.57 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 99 | $55.41 |
| 84100 | <1% | 31 | $37.55 | |
| 82550 | <1% | 15 | $23.41 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13 | $5.87 |
| A9270 | Non-covered item or service | <1% | 7,025 | $2.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $2.38 |
| J2704 | Injection, propofol, 10 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMINCHER, JEFF (SENIOR VP REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Texas Health Harris Methodist Hospital Fort Worth | Fort Worth, TX | $13.83M |
| Texas Health Presbyterian Hospital Dallas | Dallas, TX | $5.33M |
| Texas Health Harris Methodist Hospital Southwest Fort Worth | Fort Worth, TX | $5.20M |
| Texas Health Presbyterian Hospital Kaufman | Kaufman, TX | $4.09M |
| Texas Health Presbyterian Hospital Denton | Denton, TX | $3.84M |
| Texas Health Harris Methodist Hospital Stephenville | Stephenville, TX | $3.69M |
| Texas Health Harris Methodist Hospital Hurst-Euless-Bedford | Bedford, TX | $3.57M |
| Texas Health Presbyterian Hospital Plano | Plano, TX | $2.32M |
| Texas Health Harris Methodist Hospital Cleburne | Cleburne, TX | $2.31M |
| Texas Health Harris Methodist Hospital Azle | Azle, TX | $2.14M |
| Texas Health Harris Methodist Hospital Alliance | Fort Worth, TX | $986K |
| Texas Health Presbyterian Hospital Allen | Allen, TX | $965K |
| Texas Health Hospital Frisco | Frisco, TX | $473K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.